Subsidiary of ApicHope Pharmaceutical Group (300723.SZ), the innovative drug APH03571 tablet has been accepted for clinical trial registration application.

16:20 26/03/2026

Yipinho Pharmaceutical (300723.SZ) announced that recently, its wholly-owned subsidiary, Guangzhou Yipinho Pharmaceutical Co., Ltd., independently developed innovative drug APH03571 tablets, and the application for the clinical trial of the drug has been accepted by the State Food and Drug Administration, receiving an "Acceptance Notice".

ApicHope Pharmaceutical Group (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou ApicHope Pharmaceutical Group Pharmaceutical Co., Ltd., has successfully applied for clinical trials of the innovative drug APH03571 tablets developed independently by the company. The application has been accepted by the National Medical Products Administration, and the company has received the "Acceptance Notice". APH03571 is a treatment drug developed by the company for adult patients with relapsed or refractory acute myeloid leukemia (AML) carrying FLT3 mutations (full name: FMS-like tyrosine kinase 3).

KUNLUN ENERGY (00135) spent HKD 6.7361 million to repurchase 900,000 shares on March 26th.

TIAN CHANG GP (02182) releases annual performance results, with shareholders' net loss of 14.58 million Hong Kong dollars, an increase of 5.80% year-on-year.

GREAT EAGLE H (00041) issued 53,000 shares according to the share plan.

KUNLUN ENERGY (00135) spent HKD 6.7361 million to repurchase 900,000 shares on March 26th.

TIAN CHANG GP (02182) releases annual performance results, with shareholders' net loss of 14.58 million Hong Kong dollars, an increase of 5.80% year-on-year.

GREAT EAGLE H (00041) issued 53,000 shares according to the share plan.